'Multiple Myeloma Drug Market Will Reach $9.9 Billion in 2015' Predicts Visiongain Report

English
4 Pages
Read
Download
Downloading requires you to have access to the YouScribe library
Learn all about the services we offer

Description

'Multiple Myeloma Drug Market Will Reach $9.9 Billion in 2015' Predicts Visiongain Report PR Newswire LONDON, September 19, 2012 LONDON, September 19, 2012 /PRNewswire/ -- A new report by visiongain predicts that the world market for multiple myeloma drug sales will reach $9.9bn in 2015. That revenue forecast and others appear in World Multiple Myeloma Drug Treatment Market 2012-2022, published in September 2012. Visiongain is a business information provider based in London, UK. Visiongain forecasts that the multiple myeloma treatment market will expand rapidly with the approval of new drugs. The market is already one of the most dynamic segments in oncology, revolutionised by the 2006 approval of Celgene's Thalomid and then Revlimid, and Janssen's Velcade. In July 2012, the market reached a new milestone with the approval of Onyx's Kyprolis, a proteasome inhibitor with an improved safety profile and potential to be another blockbuster. The pharmaceutical industry analyst in visiongain, said: "The years 2012 to 2013 will see two important new products reach the market, Onyx's Kyprolis and Celgene's Actimid. Both of these have advantages over current drugs, but they're basically incremental improvements on what we already have - proteasome inhibitors and immunomodulators. "The next real shift for the market will come with the approval of newer mechanisms of action.

Subjects

Informations

Published by
Reads 8
Language English
Report a problem
'Multiple Myeloma Drug Market Will Reach $9.9 Billion in 2015' Predicts Visiongain Report
PR Newswire LONDON, September 19, 2012
LONDON,September 19, 2012/PRNewswire/ --A new report by visiongain predicts that the world market for multiple myeloma drug sales will reach$9.9bnin 2015. That revenue forecast and others appear in World Multiple Myeloma Drug Treatment Market 2012-2022, published in September 2012. Visiongain is a business information provider based in London, UK.
Visiongain forecasts that the multiple myeloma treatment market will expand rapidly with the approval of new drugs. The market is already one of the most dynamic segments in oncology, revolutionised by the 2006 approval of Celgene's Thalomid and then Revlimid, and Janssen's Velcade. InJuly 2012, the market reached a new milestone with the approval of Onyx's Kyprolis, a proteasome inhibitor with an improved safety profile and potential to be another blockbuster. The pharmaceutical industry analyst in visiongain, said: "The years 2012 to 2013 will see two important new products reach the market, Onyx's Kyprolis and Celgene's Actimid. Both of these have advantages over current drugs, but they're basically incremental improvements on what we already have -proteasome inhibitors and immunomodulators. "The next real shift for the market will come with the approval of newer mechanisms of action. Promising candidates in the pipeline include HDAC inhibitors, kinase inhibitors and orally-bioavailable second-generation proteasome inhibitors. However, perhaps the most exciting pipeline drug is elotuzumab by BMS and Abbott, a CS1 glycoprotein-targeting mAb, which has recorded high response rates in phase II trials. Behind elotuzumab, there are 30 or so other mAbs targeting this market, and they could make a major impact, alongside other new biologics." Visiongain's report shows revenue forecasts to 2022 at overall world market, product and national level. Research, data and analyses cover activities of Celgene, Johnson & Johnson, Novartis, Onyx and other pharmaceutical and biotechnology companies. That study discusses R&D and commercial news and predicts revenues to 2022 in leading national markets. The work analyses the US,Japan,Germany, France, the UK,Spain,Italy(EU5),Brazil,Russia,IndiaandChina(BRIC). World Multiple Myeloma Drug Treatment Market 2012-2022 adds to visiongain's range of analytical reports on industries and markets in healthcare. For sample pages and further information concerning the visiongain report The World Multiple Myeloma Drug Treatment Market 2012-2022 please visit http://www.visiongain.com/Report/895/World-Multiple-Myeloma-Drug-Treatment-Market-2012-2022 For an executive summary please contact: Email: Sara Peerun on sara.peerun@visiongainglobal.com Tel: +440 207336 6100
Companies Listed in the report include AB Science Abbott Abiogen Acceleron AdaptImmune Aeterna Zentaris Allos Therapeutics Alza Amgen Ariad Pharmaceuticals Arkansas Cancer Research Center Arno Therapeutics Array BioPharma Ascenta Therapeutics Astellas Astex Therapeutics AstraZeneca Bayer Ben Venue Laboratories Biogen Idec Biotest Pharmaceuticals Boehringer Ingelheim Bristol-Myers Squibb Broad Institute Calistoga Pharmaceuticals Callisto Pharmaceuticals Cancer Research UK Celgene Cell Genesys Cephalon Chiron Chugai Pharmaceuticals Columbia University CombinatoRx Compugen Constellation Pharmaceuticals Curis CyDex Cytokinetics Cytopia CytRx Corporation Eli Lilly EntreMed Epizyme European Medicines Agency (EMEA/EMA) Facet Biotech Food and Drug Administration (US FDA) Genentech Genmab Genzyme
Geron GlaxoSmithKline Handok Human Genome Sciences Immune System Therapeutics ImmunoGen Immunomedics Incyte Corporation Infinity Pharmaceuticals Intellikine Italfarmaco Jakafi Janssen Johnson & Johnson Karyopharm Therapeutics Kayaku Zentaris Keryx Biopharmaceuticals Kirin Pharma Kosan Biosciences Kyowa Hakko Kirin Lipomed MacroGenics Mayo Clinic MD Anderson Cancer Center Merck & Co. MethylGene Micromet Millennium Pharmaceuticals MorphoSys Multiple Myeloma Research Consortium (MMRC) Multiple Myeloma Research Foundation Natco Pharma National Cancer Institute National Institute for Health and Clinical Excellence (NICE) Nereus Pharmaceuticals Nippon Shinyaku Novartis Novo Nordisk Oncolytics Oncovir Ono Onyx Pharmaceuticals PDL BioPharma Pfizer Pharmacia Pharmacyclics PharmaMar Pierre Fabre Prochon Biotech Prometheus Labs Protein Design
Regeneron Roche Rockefeller University Salmedix Schering-Plough Scios Seattle Genetics Senesco Technologies Sidney Kimmel CCC Sloan Kettering Sugen Sun Pharma Sydney Kimmel CCC Synta Pharmaceuticals Takeda Targa Therapeutics Teva Pharmaceutical Industries Threshold Pharmaceuticals Translational Genomics Research Institute UAMS University of Arkansas University of Illinois Vertex Weill Cornell Medical College World Health Organization (WHO) Xencor Zeltia Zenyaku Kogyo For an executive summary please contact: Email: Sara Peerun on sara.peerun@visiongainglobal.com Tel: +44 (0) 20 7336 6100 Notes for Editors About visiongain Visiongain is one of the fastest growing and most innovative independent media companies inEurope. Based inLondon, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors. Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on. If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100